Trial of Anifrolumab in Active Systemic Lupus ErythematosusEric F. Morand, Raj Tummala, Richard Furie et al.|New England Journal of Medicine|2019Cited by 1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 updateAntonis Fanouriakis, Dimitrios T. Boumpas, Y K Onno Teng et al.|Annals of the Rheumatic Diseases|2023Cited by 913
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)Kate Franklyn, Eric F. Morand, Chak Sing Lau et al.|Annals of the Rheumatic Diseases|2015Cited by 728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task forceRonald van Vollenhoven, Matthias Schneider, Marta Mosca et al.|Annals of the Rheumatic Diseases|2014Cited by 726
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosusJing He, Zhanguo Li, Xia Zhang et al.|Nature Medicine|2016Cited by 570